Clinical Trial Update: Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab as monotherapy in previously treated locally advanced unresectable or metastatic colorectal cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-21